4-hydroxycyclophosphamide has been researched along with Cancer of Ovary in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Finkler, NJ; Fruehauf, JP; Holloway, RW; Li, KT; McLaren, CE; Mehta, RS; Parker, RJ | 1 |
| Berman, ML; Burger, RA; Disaia, PJ; Fruehauf, JP; Kyshtoobayeva, AS; Manetta, A; Mehta, RS; Monk, BJ; Tewari, KS; Yu, IR | 1 |
| Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; van Dam, SM | 1 |
| Beijnen, JH; Doodeman, VD; Ekhart, C; Huitema, AD; Rodenhuis, S; Smits, PH | 1 |
| Petru, E; Pöch, G; Vychodil-Kahr, S | 1 |
| Angioli, R; Averette, HE; Baibl, A; Hightower, RD; Nguyen, HN; Perras, JP; Sevin, BU; Untch, M | 1 |
| Averette, HE; Gerhardt, RT; Guerra, L; Perras, JP; Petru, E; Ramos, R; Sevin, BU | 1 |
2 trial(s) available for 4-hydroxycyclophosphamide and Cancer of Ovary
| Article | Year |
|---|---|
Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Cyclophosphamide; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Rate; Treatment Outcome | 2002 |
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
Topics: Adolescent; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Neoplasms; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Phosphoramide Mustards; Prodrugs; Thiotepa; Time Factors; Triethylenephosphoramide | 2005 |
5 other study(ies) available for 4-hydroxycyclophosphamide and Cancer of Ovary
| Article | Year |
|---|---|
Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.
Topics: Cisplatin; Cyclophosphamide; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Metastasis; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Topotecan | 2005 |
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Topics: Adolescent; Adult; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aryl Hydrocarbon Hydroxylases; Base Sequence; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA Primers; Female; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Genetic; Retinal Dehydrogenase | 2008 |
Sigmoid model versus median-effect analysis for obtaining dose-response curves for in vitro chemosensitivity testing.
Topics: Antibiotics, Antineoplastic; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Linear Models; Mitomycin; Models, Statistical; Ovarian Neoplasms; Tumor Cells, Cultured | 1999 |
Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; In Vitro Techniques; Ovarian Neoplasms; Recurrence | 1992 |
Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; In Vitro Techniques; Neoplasm Recurrence, Local; Ovarian Neoplasms | 1991 |